Arizona lawmakers have approved a bill in committee to promote research into the medical potential of psilocybin mushrooms for a variety of conditions, which could inform future reforms to more broadly allow access to psychedelic-assisted therapy.
The House Military Affairs & Public Safety Committee unanimously passed the legislation from Reps. Kevin Payne (R), Jennifer Longdon (D), Stacey Travers (D) and Sen. T. J. Shope (R) in a 15-0 vote on Monday. The bill was introduced last month.
The proposal is focused on psilocybin research, providing $30 million in grants over the course of three years for scientists to study the impact of the psychedelic on 13 different conditions such as post-traumatic stress disorder (PTSD), depression, anxiety, long COVID symptoms and substance misuse disorder.
It wouldn’t legalize psilocybin like lawmakers in several other states are aiming to accomplish, but the research that the bill would support is meant to steer the conversation about broader reforms down the line.
The research grants would be appropriated for phase I, II and III clinical trials that are “capable of being approved by the United States Food and Drug Administration (FDA) to evaluate the effects of whole mushroom psilocybin” for the designated conditions.
“The public
Read full article on Marijuana Moment
